Junmin Y. Chen

20 Cha Zhong Rd
Fuzhou, 350005, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

Journal: American journal of hematology

Published: March 23, 2026

Pathway alteration burden derived from whole-exome sequencing is associated with survival in primary central nervous system lymphoma.

Pathway alteration burden derived from whole-exome sequencing is associated with survival in primary central nervous system lymphoma.

Journal: British journal of haematology

Published: March 20, 2026

Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics.

Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics.

Journal: American journal of hematology

Published: January 22, 2026

Increased IL4I1 expression predicts poor survival and modulates the immune microenvironment in acute myeloid leukemia.

Increased IL4I1 expression predicts poor survival and modulates the immune microenvironment in acute myeloid leukemia.

Journal: Journal of translational medicine

Published: October 30, 2025

Prognostic genes related to mitochondrial dynamics and mitophagy in diffuse large B-cell lymphoma are identified and validated using an integrated analysis of bulk and single-cell RNA sequencing.

Prognostic genes related to mitochondrial dynamics and mitophagy in diffuse large B-cell lymphoma are identified and validated using an integrated analysis of bulk and single-cell RNA sequencing.

Journal: Frontiers in immunology

Published: August 16, 2025

B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.

B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.

Journal: Molecular carcinogenesis

Published: February 27, 2025

Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.

Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.

Journal: Haematologica

Published: February 05, 2025

68 Ga-Pentixafor PET in Combination With MRI Improves the Differential Diagnosis of Glioblastoma and Primary Central Nervous System Lymphoma.

68 Ga-Pentixafor PET in Combination With MRI Improves the Differential Diagnosis of Glioblastoma and Primary Central Nervous System Lymphoma.

Journal: Clinical nuclear medicine

Published: January 06, 2025

Role of BACH1 in multiple myeloma.

Role of BACH1 in multiple myeloma.

Journal: Hematology (Amsterdam, Netherlands)

Published: May 20, 2024

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.

Journal: Signal transduction and targeted therapy

Published: April 09, 2024

NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway.

NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway.

Journal: Cell communication and signaling : CCS

Published: December 19, 2023

SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.

SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.

Journal: Molecular carcinogenesis

Published: September 13, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026